Atlanta, Georgia — August 6, 2025 — Leads & Copy — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) will release its second quarter 2025 financial results on Wednesday, August 13, 2025, prior to the opening of financial markets, the company announced today. The biopharmaceutical company is focused on developing new medicines to treat pain and fatigue-related disorders. Dogwood’s pipeline includes a non-opioid analgesic program featuring Halneuron®, and an antiviral program with IMC-1 and IMC-2. Interim data from the Halneuron® Phase 2 CINP study are expected in Q4 of 2025. IMC-1 is being developed as a treatment for FM and IMC-2 for LC, with an agreement reached with the FDA to use fatigue reduction as the primary endpoint for future IMC-2 LC research.
Contact:
IR@dwtx.com
Source: Dogwood Therapeutics
